 |
0 Diseases |  |
1 Trial |
|
1 Trial |  |
4 News |  |
- || Bendeka (bendamustine rapid infusion) / Eagle Pharma, Teva, SymBio Pharma
Trial completion, Combination therapy: Phase I/II Study of SyB L-0501RI in Combination With Rituximab to Treat Lymphoma (clinicaltrials.gov) - Jun 28, 2023
P1/2, N=37, Completed, Sponsor: SymBio Pharmaceuticals
Unknown status --> Completed
- | Bendeka (bendamustine rapid infusion) / Eagle Pharma, Teva, SymBio Pharma
#EaglePharmaceuticals World-Wide Sales for #BENDEKA was 41.38m USD in Q4 2022 (Up 1279%) https://t.co/WRNUBCXs5N (Twitter) - Apr 17, 2023
- || Bendeka (bendamustine rapid infusion) / Eagle Pharma, Teva, SymBio Pharma
P1/2 data, Clinical Trial,Phase I, Clinical Trial,Phase II, Journal: A phase I/II study of 10-min dosing of bendamustine hydrochloride (rapid infusion formulation) in patients with previously untreated indolent B-cell non-Hodgkin lymphoma, mantle cell lymphoma, or relapsed/refractory diffuse large B-cell lymphoma in Japan. (Pubmed Central) - Jul 24, 2022
P1/2
This study showed that bendamustine is safe, well-tolerated and effective for patients with previously untreated iNHL, MCL or rrDLBCL. Pharmacokinetic data were equivalent to those obtained outside of Japan.
- ||| Bendeka (bendamustine rapid infusion) / Eagle Pharma, Teva, SymBio Pharma
M&A: $EGRX Eagle Pharmaceuticals Reaches Settlement Agreement with Hospira Related to BENDEKA® (bendamustine hydrochloride) until January 17, 2028 https://t.co/BKFzapP0oJ (Twitter) - Apr 19, 2022
- || Bendeka (bendamustine rapid infusion) / Eagle Pharma, Teva, SymBio Pharma
Enrollment open, Combination therapy: Phase I/II Study of SyB L-0501RI in Combination With Rituximab to Treat Lymphoma (clinicaltrials.gov) - Oct 30, 2019
P1/2, N=36, Recruiting, Sponsor: SymBio Pharmaceuticals
Pharmacokinetic data were equivalent to those obtained outside of Japan. Not yet recruiting --> Recruiting
- || Bendeka (bendamustine rapid infusion) / Eagle Pharma, Teva, SymBio Pharma
New P1/2 trial, Combination therapy: Phase I/II Study of SyB L-0501RI in Combination With Rituximab to Treat Lymphoma (clinicaltrials.gov) - Apr 3, 2019
P1/2, N=36, Not yet recruiting, Sponsor: SymBio Pharmaceuticals